K

Knight Therapeutics Inc
TSX:GUD

Watchlist Manager
Knight Therapeutics Inc
TSX:GUD
Watchlist
Price: 5.25 CAD 0.38% Market Closed
Market Cap: 529.2m CAD
Have any thoughts about
Knight Therapeutics Inc?
Write Note

Knight Therapeutics Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Knight Therapeutics Inc
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
K
Knight Therapeutics Inc
TSX:GUD
Cost of Revenue
-CA$180.4m
CAGR 3-Years
-11%
CAGR 5-Years
-143%
CAGR 10-Years
N/A
Canopy Growth Corp
TSX:WEED
Cost of Revenue
-CA$192.2m
CAGR 3-Years
31%
CAGR 5-Years
9%
CAGR 10-Years
-91%
Sundial Growers Inc
NASDAQ:SNDL
Cost of Revenue
-CA$689.3m
CAGR 3-Years
-137%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Cost of Revenue
-$94.9m
CAGR 3-Years
2%
CAGR 5-Years
-33%
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Curaleaf Holdings Inc
CNSX:CURA
Cost of Revenue
-$1.3B
CAGR 3-Years
-55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Knight Therapeutics Inc
Glance View

Market Cap
530.1m CAD
Industry
Pharmaceuticals

Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. The company is headquartered in Montreal, Quebec and currently employs 660 full-time employees. The company went IPO on 2014-02-28. The firm's principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The Company’s products include BIJUVA Estradiol and Progesterone capsule, IMVEXXY Estradiol vaginal inserts, IBSRELA Tenapanor tablets, TRELSTAR Prostate Triptorelin, TRELSTAR Endometriosis Triptorelin, ILUVIEN Fluocinolone acetonide, Nerlynx Neratinib Tablets, Nerlynx Patient Checklist, Nerlynx Prescriber Checklist, Burinex Bumetanide, Probuphine Buprenorphine implant, Movantik Naloxegol and Neuragen. The company owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Its subsidiaries operates under United Medical, Biotoscana Farma and Laboratorio LKM.

GUD Intrinsic Value
4.95 CAD
Overvaluation 6%
Intrinsic Value
Price
K

See Also

What is Knight Therapeutics Inc's Cost of Revenue?
Cost of Revenue
-180.4m CAD

Based on the financial report for Sep 30, 2024, Knight Therapeutics Inc's Cost of Revenue amounts to -180.4m CAD.

What is Knight Therapeutics Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-143%

Over the last year, the Cost of Revenue growth was 0%. The average annual Cost of Revenue growth rates for Knight Therapeutics Inc have been -11% over the past three years , -143% over the past five years .

Back to Top